FREE Shipping on orders over $200 USD

Email

support@elyxaminos.com

Tesamorelin 20mg

$ 952.000

GHRH Analogue · Visceral Fat · Endogenous IGF-1 · Research Only

  • Tesamorelin 20mg liofilizado para reconstitución con 2ml de agua bacteriostática
  • Concentración: 10,000 mcg/ml · Dosis U-100: 100 mcg/u
  • SubQ Route · Refrigerated 2-8°C
  • Research material only. Not approved for human use by the FDA.

Out of stock

Global Elite Shipping

Fast shipments from our logistics center in the USA to worldwide.

Guaranteed Purity

Each batch includes a Certificate of Analysis (COA) for research grade.

Secure & Private Payment

Encrypted transactions to protect your cellular health investment.

Description

Tesamorelin 20mg

GHRH analog · Visceral fat · Endogenous IGF-1 · Research Only

What is it and how does it work?

Tesamorelin is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH). It binds to the GHRH-R receptor on pituitary somatotrophs and stimulates pulsatile release of endogenous growth hormone, with documented increases in serum IGF-1 in clinical studies. The literature describes a preferential effect on abdominal visceral adipose tissue in cohorts with HIV-associated lipodystrophy.

Clinical evidence: Falutz et al. (NEJM 2007, PMID 17984164) reported a reduction in visceral fat in patients with HIV-associated lipodystrophy following treatment with 2 mg/day subcutaneous (SubQ) 15-20% for 26 weeks. Stanley et al. (JCI 2014, PMID 24911148) reported improvement in hepatic steatosis in nonalcoholic fatty liver disease. Research use only—no FDA-approved human use outside the specific indication of HIV-associated lipodystrophy (Egrifta).

Reconstitution and dosage

  • Vial 20 mg liofilizado
  • Bacteriostatic water: 2 ml
  • Resulting concentration: 10,000 mcg/ml
  • Per unit U-100: 100 mcg · verificación: 10,000 ÷ 100 = 100 mcg/u ✓
  • Conservation Refrigerate 2–8°C · Use within 28–30 days after reconstituting

Volume Conversion Chart (U-100 syringe)

U-100 equivalent Volume Load (mcg)
25 years old 0.25 milliliters 2,500 mcg
50 u 0.50 mL 5,000 micrograms
100 u 1.00 mL 10,000 mcg

Documented evidence

  • Falutz J et al., NEJM 2007 (PMID 17984164) — Tesamorelin 2mg/day SubQ × 26 wks reduces visceral fat in HIV lipodystrophy
  • Stanley TL et al., JCI 2014 (PMID 24911148) — Improvement of hepatic steatosis
  • Adrian S et al., Clin Infect Dis 2018—Improvement in IGF-1 and Body Composition

Practical notes

  • Via documented in clinical literature: SubQ once daily (typically night)
  • The effect on IGF-1 is dose-dependent; literature reports IGF-1 monitoring every 6-12 weeks
  • Research Stack: Tesamorelin + CJC/Ipa amplifies the GH axis; with BPC-157 for tissue regeneration

Contraindications and precautions

  • For research use only. No human use approved by FDA outside of Egrifta® for HIV lipodystrophy. No established safety data for other uses. Not for human use.

Research material only. Not approved for human use by the FDA. This product is intended for scientific research purposes in controlled laboratory settings only. It is not a drug. Not for human or animal administration, therapeutic use, or diagnostic use.

Select your currency

Legal Notice

All products are sold in powder (lyophilized) form and require reconstitution with a suitable diluent for research purposes only. Laboratory supplies (e.g., syringes, bacteriostatic water, etc.) are not included. Dosage instructions are not provided.

We comply with all local and national laws and regulations related to product sales. exclusively for research.
We are not a pharmacy, nor do we offer, promote, or provide any advice for human or animal consumption.

Please carefully review our Terms and Conditions Before making a purchase on our website.

You must be over 21 years old and a licensed research professional.

When clicking on “I accept”, you confirm that you have read and accepted the Terms and Conditions set forth above.

x
Cart
Your cart is empty
Let's go shopping!
Start shopping